1.4% SEP Increase Impacts Pharmaceutical Investment
Understanding the 1.4% SEP increase: why the pharmaceutical sector is urging a reconsideration of the price cap.
Lilly Hits $1 Trillion Valuation with Weight-Loss Success
Eli Lilly hits $1 trillion valuation, marking a historic milestone in the pharmaceutical industry with successful weight-loss drugs.
Adcock Ingram: A picture of resilience in a challenging market
Pharmaceutical stalwart Adcock Ingram presents a compelling case for investors seeking resilience amidst potential market turbulence. The group boasts a robust track record, with a mere 3% dip in headline earnings per share (HEPS) during the challenging Covid-impacted year of 2021. It was their worst annual performance in a decade. Since 2015, Adcock has delivered…...
Clicks Group: The Value Behind the Price Tag
Clicks Group is undeniably a powerhouse on the JSE. It is widely recognised as a well-managed and resilient business. However, a persistent question dogs potential investors, particularly those inclined towards scepticism: is Clicks Group simply too expensive to justify buying? While it’s true that Clicks trades at a premium compared to many other retailers, this…...
Discovery reports a 34% increase in first-half earnings
Discovery announces an increase in first-half headline earnings, fuelled by strong performances in the health insurance sector and the Vitality programme.